Odyssey Capital Advisors Inc. Buys New Shares in Astrazeneca Plc $AZN

Odyssey Capital Advisors Inc. bought a new stake in Astrazeneca Plc (NYSE:AZN) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 3,233 shares of the company’s stock, valued at approximately $567,000.

A number of other hedge funds have also added to or reduced their stakes in AZN. Bank of Montreal Can grew its position in Astrazeneca by 344.6% in the third quarter. Bank of Montreal Can now owns 3,478,114 shares of the company’s stock valued at $266,841,000 after purchasing an additional 2,695,793 shares in the last quarter. Holocene Advisors LP grew its position in Astrazeneca by 41.8% in the third quarter. Holocene Advisors LP now owns 6,129,194 shares of the company’s stock valued at $470,232,000 after purchasing an additional 1,807,565 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich grew its position in Astrazeneca by 11,190.9% in the fourth quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,806,877 shares of the company’s stock valued at $317,107,000 after purchasing an additional 1,790,874 shares in the last quarter. Raymond James Financial Inc. grew its position in Astrazeneca by 64.8% in the second quarter. Raymond James Financial Inc. now owns 3,783,251 shares of the company’s stock valued at $264,373,000 after purchasing an additional 1,487,662 shares in the last quarter. Finally, Bank of America Corp DE grew its position in Astrazeneca by 4.7% in the third quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock valued at $2,503,614,000 after purchasing an additional 1,461,786 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

Astrazeneca Stock Performance

Shares of AZN stock opened at $181.62 on Monday. The stock has a market cap of $281.67 billion, a P/E ratio of 27.27, a P/E/G ratio of 1.49 and a beta of 0.26. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. The company has a fifty day moving average price of $192.38 and a two-hundred day moving average price of $182.16. Astrazeneca Plc has a one year low of $136.16 and a one year high of $212.71.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. The firm had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. As a group, equities analysts predict that Astrazeneca Plc will post 10.26 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. UBS Group reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Friday, April 10th. DZ Bank upgraded shares of Astrazeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 29th. Weiss Ratings began coverage on shares of Astrazeneca in a research note on Wednesday, March 11th. They issued a “buy (b)” rating for the company. TD Cowen reiterated a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Astrazeneca in a research note on Wednesday, May 13th. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Astrazeneca has a consensus rating of “Moderate Buy” and an average price target of $205.33.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.